Profusa, Inc. (PFSA) Stock Price & Analysis
Profusa, Inc. (PFSA) fell 2.84% to USD 1.71 as of July 25, 2026 at 09:49 UTC, according to Nexqual real-time market data.
PFSA last closed at USD 1.76; the session ranged USD 1.6–1.8 on volume of 25,230 shares. Market capitalization is $906,300, with a 52-week range of USD 1.6–4,162.5 (NCM). Source: Nexqual, July 25, 2026 at 09:49 UTC.
Key Statistics (as of July 25, 2026 at 09:49 UTC)
| Price | USD 1.71 |
|---|---|
| Change | ▼ 2.84% (down) |
| Previous Close | USD 1.76 |
| Open | USD 1.8 |
| Day Range | USD 1.6 – 1.8 |
| 52-Week Range | USD 1.6 – 4,162.5 |
| Volume | 25,230 shares |
| Market Cap | $906,300 |
| Exchange | NCM |
Technical Analysis (PFSA)
Nexqual's technical model rates PFSA "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.19 (neutral) |
| vs SMA50 | Below (USD 5.45) |
| MACD | -1.12 (negative) |
Analyst Ratings (PFSA)
Wall Street analysts rate PFSA "None", per Nexqual as of July 25, 2026 at 09:49 UTC.
| Consensus Rating | None |
|---|
Earnings (PFSA)
Source: Nexqual, July 25, 2026 at 09:49 UTC.
Financials & Fundamentals (PFSA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.02 |
| Total Cash | $375,000 |
| Total Debt | $12.54M |
| Free Cash Flow | $-13.87M |
Source: Nexqual, July 25, 2026 at 09:49 UTC.
Financial Health Score (PFSA)
Nexqual rates Profusa, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 09:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $375K cash vs $13M debt |
| Cash Flow | Weak — Operating cash flow -$18M |
| Efficiency | Mixed — No data |
Ownership (PFSA)
| Insider Ownership | +1.02% |
|---|---|
| Institutional Ownership | +0.58% |
| Shares Outstanding | 530,000 |
| Float | 181,855 |
| Short % of Float | +10.06% |
Source: Nexqual, July 25, 2026 at 09:49 UTC.
Leadership (PFSA)
Profusa, Inc. is led by Ben Chung-Bin Hwang (age 57), CEO & Chairman, per Nexqual as of July 25, 2026 at 09:49 UTC.
| CEO & Chairman | Ben Chung-Bin Hwang (age 57) |
|---|---|
| Chief Financial Officer | Fred S. Knechtel (age 64) |
| Co-founder, Chief Scientific Officer & Head of Research | William McMillan (age 74) |
From Profusa, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States.
- It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery.
- The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ASBP | Aspire Biopharma Holdings, Inc. | USD 7.26 | ▼ 6.44% |
| AZI | Autozi Internet Technology (Glo | USD 1.16 | ▼ 7.94% |
| KIDZ | KIDZ AI Inc. | USD 0.42 | ▼ 26.86% |
| PAVS | Paranovus Entertainment Technol | USD 4.83 | ▲ 24.48% |
| SKYQ | Sky Quarry Inc. | USD 4.7 | ▲ 13.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:49 UTC. This page is informational and not investment advice.